Discover
MDWD
MediWound Ltd.
14.28
2 x 14.28
2 x 14.34
bid
ask
-
0.32
2.19%
undefined @ 04:00 PM
14.26 -0.02 (0.14%)
| Ytd | -22.64% | |
| 1y | -28.85% |
14.07
day range
14.58
13.54
52 week range
21.11
| Open | 14.47 | Prev Close | 14.60 | Low | 14.07 | High | 14.58 | Mkt Cap | 155.12M |
| Vol | 108.03K | Avg Vol | 88.16K | EPS | -2.26 | P/E | -6.32 | Forward P/E | -7.96 |
| Beta | 0.14 | Short Ratio | 18.59 | Inst. Own | 45.50% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 14.91 | 200-d Avg | 17.01 | 1yr Est | 29.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-26 | 2024-09 | -0.48 | -0.98 | -0.5 | -104.17% |
| 2024-08-14 | 2024-06 | -0.42 | -0.68 | -0.26 | -61.90% |
| 2024-05-29 | 2024-03 | -0.4 | -0.39 | 0.01 | 2.50% |
| 2024-03-21 | 2023-12 | -0.23 | -0.19 | 0.04 | 17.39% |
| 2023-11-21 | 2023-09 | -0.45 | -0.24 | 0.21 | 46.67% |
| 2023-08-15 | 2023-06 | -0.41 | 0.1 | 0.51 | 124.39% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-27 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-10-11 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-08-15 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-07-16 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-05-30 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-03-22 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Investor AB | 872.09K | 15.41M | 6.83% |
| 2024-09-29 | Yelin Lapidot Holdings Management Ltd. | 750.74K | 13.27M | 5.88% |
| 2024-09-29 | Rosalind Advisors, Inc. | 628.05K | 11.10M | 4.92% |
| 2024-09-29 | Blackrock Inc. | 433.00K | 7.65M | 3.39% |
| 2024-09-29 | Balyasny Asset Management LLC | 165.74K | 2.93M | 1.30% |
| 2024-09-29 | Sargent Investment Group, LLC | 117.19K | 2.07M | 0.92% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | iShares Russell 2000 ETF | 206.38K | 3.65M | 1.62% |
| 2024-10-30 | ARK ETF Tr-ARK Israel Innovative Technology ETF | 115.77K | 2.05M | 0.91% |
| 2024-08-30 | Fidelity Small Cap Index Fund | 81.74K | 1.44M | 0.64% |
| 2024-10-30 | iShares Russell 2000 Growth ETF | 70.15K | 1.24M | 0.55% |
| 2024-08-30 | Vanguard Russell 2000 Index Fund | 32.38K | 572.08K | 0.25% |
| 2024-07-30 | 1290 Fds-1290 Essex Small Cap Growth Fd | 21.23K | 375.19K | 0.17% |
Split
| Split | Date |
|---|---|
| 1 : 7 | 2022-12-20 |